Scottish Biotech Bead Biopharma Emerges From Stealth Mode with Novel Cancer Drug Platform

Bead BioPharma, a Scottish life sciences company backed by Archangels, today announced its emergence from stealth mode following the submission of its first patent, a milestone that marks the company’s formal entry into one of the most commercially active sectors in global oncology.

The company is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes described as ‘guided missiles’, which are designed to deliver toxic, cancer-killing agents directly to tumor cells while sparing healthy tissue. ADCs have become one of the highest priority areas of drug development, with multiple billion-dollar licensing deals and acquisitions completing in 2026 alone. Despite the pace of investment, a fundamental engineering problem persists: the chemical bond holding these therapies together is prone to breaking down before reaching the target, causing side effects and reducing effectiveness.

Bead BioPharma has developed a proprietary platform of technologies that aim to make ADCs more durable, reducing unintended toxicity and improve their performance in patients. While most approaches to this problem focus on targeting biology, Bead’s platform addresses it through chemistry, which the company believes represents a genuinely differentiated position in the market.

The company has demonstrated its platform in laboratory stability models using existing commercial ADCs, with a confirmed improvement in stability and reduced off-target toxicity in cell-based models. It has also independently validated the technology’s scalability at two independent laboratories, a key step toward commercial application. A second patent covering the use of the method in the development of novel ADC therapies is in progress.

The platform has applications both in new drug candidates and in existing ADC therapies already approved or in clinical trials, with potential to generate improved versions of existing products and extend their commercial life.

Interim CEO Dan Ozanne and chair Mike Sun, formerly of Seagen, one of the pioneering companies in the ADC field, will attend the 5th World ADC Summit in South Korea this month, where the team will present data from its program for the first time.

We’ve been working hard under the radar to build the scientific foundation of our platform, protect our IP, and assemble a world-class team in the field of biologics and ADC discovery, development and manufacture. We’re at the point now where we have the data and the patent filings to start making ourselves known. Our proprietary platform tackles the stability challenge that the whole field is grappling with, and our approach through chemistry rather than biology gives us a genuinely different angle. We’re looking forward to presenting our results in South Korea and beginning to engage with potential partners.”

Dan Ozanne, Interim CEO, Bead BioPharma